Design of multi-target compounds as AChE, BACE1, and amyloid-β1-42 oligomerization inhibitors: In silico and in vitro studies

Journal of Alzheimer's Disease

Volumn 41, Issue 4, 2014, Pages 1073-1085

  Hernández Rodríguez, Maricarmen ^a   Correa Basurto, José ^a   Martínez Ramos, Federico ^a   Padilla Martínez, Itzia Irene ^a   Benítez Cardoza, Claudia G ^a   Mera Jiménez, Elvia ^a   Rosales Hernández, Martha Cecilia ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Acetylcholinesterase; Alzheimer's disease; amyloid ; inhibitor; site A PP cleaving enzyme 1

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[1-42]; ANTIOXIDANT; BETA SITE AMYLOID PROTEIN PRECURSOR CLEAVING ENZYME 1; CHOLINESTERASE INHIBITOR; ENZYME; GALANTAMINE; M 1; M 4; MONOMER; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; ENZYME INHIBITOR; OLIGOPEPTIDE; OM99-2; PEPTIDE FRAGMENT; SECRETASE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; BINDING AFFINITY; COMPUTER MODEL; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; IC50; IN VITRO STUDY; MICROGLIA; MICROGLIAL CELL CULTURE; MOLECULAR DOCKING; MOUSE; NONHUMAN; OLIGOMERIZATION; PHARMACOPHORE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; TRANSGENIC MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CORTEX; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; NEWBORN; SPRAGUE DAWLEY RAT;

ACETYLCHOLINESTERASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANIMALS, NEWBORN; ANTIOXIDANTS; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; IN VITRO TECHNIQUES; MICROGLIA; MODELS, MOLECULAR; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PHYSICOCHEMICAL PROCESSES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84923652482     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140471     Document Type: Article

References (50)

1. Goedert M, Spillantini MG (2006) A century of Alzheimer's disease. Science 314, 777-781.
2. Castro A, Martinez A (2006) Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr Pharm Des 12, 4377-4387.
3. Tariot PN, Federoff HJ (2003) Current treatment for Alzheimer disease and future prospects. Alzheimer Dis Assoc Disord 17, 105-113.
4. Gilbert BJ (2013) The role of amyloid β in the pathogenesis of Alzheimer's disease. J Clin Pathol 66, 362-366.
5. Conway KA, Baxter EW, Felsenstein KM, Reitz AB (2003) Emerging beta-amyloid therapies for the treatment of Alzheimer's disease. Curr Pharm Design 9, 427-447.
6. Bignante EA, Heredia F, Morfini G, Lorenzo A (2013) Amyloid β precursor protein as a molecular target for amyloid β-induced neuronal degeneration in Alzheimer's disease. Neurobiol Aging 11, 2525-2537.
7. LeVine H (2004) Alzheimer's beta-peptide oligomer formation at physiologic concentrations. Anal Biochem 335, 81-90.
8. Tomaselli S, Esposito V, Vangone P, Van Nuland NA, Bonvin AM, Guerrini R, Tancredi T, Temussi PA, Picone D (2006) The alpha-to-beta conformational transition of Alzheimer's A beta-(1-1-42) peptide in aqueous media is reversible: A step by step conformational analysis suggests the location of beta conformation seeding. Chem Bio Chem 7, 257-267.
9. Sciarretta KL, Gordon DJ, Petkova AT, Tycko R, Meredith SC (2005) Aβ40-lactam (D23/K28) models a conformation highly favorable for nucleation of amyloid. Biochemistry 44, 6003-6014.
10. Tougu V, Tiiman A, Palumaa P (2011) Interactions of Zn (II) and Cu (II) ions with Alzheimer's amyloid-betapeptide Metal ion binding, contribution to fibrillization and toxicity. Metallomics 3, 250-261.
11. Zhu X, Su B, Wang X, Smith MA, Perry G (2007) Causes of oxidative stress in Alzheimer disease. Cell Mol Life Sci 64, 2202-2210.
12. Babic T (1999) The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry 67, 558.
13. Small DH (2005) Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: Do we need new inhibitors. Expert Opin Emerging Drugs 10, 817-825.
14. TerryAV, Buccafusco JJ (2003) The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306, 821-827.
15. Selkoe DJ, PodlisnyMB (2002) Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet 3, 67-99.
16. Cavalli A, Bolognesi ML, Capsoni S, Andrisano V, Bartolini M, Margotti E, Cattaneo A, Recanatini M, Melchiorre C (2007) A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew Chem Int Engl 46, 3689-3692.
17. Munoz-Torrero D, Camps P (2006) Dimeric and hybrid anti-Alzheimer drug candidates. Curr Med Chem 13, 399-422.
18. Savini L, Gaeta A, Fattorusso C, Catalanotti B, Campiani G, Chiasserini L, Pellerano C, Novellino E, McKissic D, Saxena A (2003) Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors. J Med Chem 46, 1-4.
19. Decker M (2006) Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase. J Med Chem 49, 5411-5413.
20. Carlier PR, ChowES, HanY, Liu J, ElYazal J, PangYP(1999) Heterodimeric tacrine-based acetylcholinesterase inhibitors: Investigating ligand-peripheral site interactions. J Med Chem 42, 4225-4231.
21. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C (2008) Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51, 347-372.
22. Sterling J, Herzig Y, Goren T, Finkelstein N, Lerner D, Goldenberg W, Miskolczi I, Molnar S, Rantal F, Tamas T, Toth G, Zagyva A, Zekany A, Finberg J, Lavian G, Gross A, Friedman R, Razin M, Huang W, Krais B, Chorev M, Youdim MB,WeinstockM(2002) Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J Med Chem 45, 5260-5279.
23. Rosini M, Antonello A, Cavalli A, Bolognesi ML, Minarini A, Marucci G, Poggesi E, Leonardi A, Melchiorre C (2003) Prazosin-related compounds. Effect of transforming the piperazinylquinazoline moiety into an aminomethyltetrahydroacridine system on the affinity for alpha1-adrenoreceptors. J Med Chem 46, 4895-4903.
24. Elsinghorst PW, Cieslik JS, Mohr K, Tränkle C, Gütschow M (2007) First gallamine-tacrine hybrid: Design and characterization at cholinesterases and the M2 muscarinic receptor. J Med Chem 50, 5685-5695.
25. John S, Thangapandian S, Sakkiah S, Lee KW (2011) Potent bace-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies. BMC Bioinformatics 15, S28.
26. Lu SH, Wu JW, Liu HL, Zhao JH, Liu KT, Chuang CK, Lin HY, Tsai WB, Ho Y (2011) The discovery of potential acetylcholinesterase inhibitors: A combination of pharmacophore modeling, virtual screening, and molecular docking studies. JBS 18, 8-51.
27. 2+ and galanthamine as the limiting step in the amyloid beta (1-42) fibrillation process. Prot Sci 22, 1320-1335.
28. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23, 3-25.
29. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Zakrzewski VG, Jr. Montgomery JA, Stratmann RE, Burant JC, Dapprich S, Millan JM, Daniels AD, Kudin KN, Strain MC, Farkas O, Tomasi J, Barone V, Cossi M, Cammi R, Mennucci B, Pomelli C, Adamo C, Clifford S, Ochterski J, Peterson GA, Ayala PY, Cui Q, Morokuma K, Malick DK, Rabuck AD, Raaghavachari K, ForMan JB, Cioslowski J, Ortiz JV, Baboul AG, Stefanov BB, Liu G, Liashenko A, Piskorz P, Komaromi I, Gomperts R, Martin RL, Fox DJ, Keith T, Al-Laham MA, Peng CY, Nanayahkara A, González C, Challacombe M, Gill PW, Johnson B, Chen W, Wong MW, Andres JL, Head-Gordon M, Replogle ES, Pople JA (1998) Gaussian 98 Revision A.7. Gaussian Inc., Pittsburgh, PA.
30. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDock-Tools4: Automated docking with selective receptor flexibility. J Comput Chem 30, 2785-2791.
31. Humphrey W, Dalke A, Schulten K (1996) VMD: Visual molecular dynamics. J Mol Graph 14, 33-38.
32. Bonting SL, Featherstone RM (1956) Ultramicro assay of the cholinesterases. Arch Biochem Biophys 61, 89-98.
33. 3+ on amyloid-β stability, oligomerization, and aggregation. J Biol Chem 286, 9646-9656.
34. Levine H (1993) Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci 2, 404-410.
35. Matharu B, Gibson G, Parsons R, Huckerby TN, Moore SA, Cooper LJ, Millichamp R, Allsop D, Austen B (2009) Galantamine inhibits β-amyloid aggregation and cytotoxicity. J Neurol Sci 280, 49-58.
36. Bondet V, Brand-Williams W, Berset C (1997) Kinetics and mechanisms of antioxidant activity using the DPPH• free radical method. Lebensm Wiss u Technol 30, 609-615.
37. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, Tang J (2000) Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290, 150-153.
38. Ghosh AK, Bilcer G, Harwood C, Kawahama R, Shin D, Hussain KA, Hong L, Loy JA, Nguyen C, Koelsch G, Ermolieff J, Tang J (2001) Structure-based design: Potent inhibitors of human brain memapsin 2 (beta-secretase). J Med Chem 44, 2865-2868.
39. Chang WP, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM, Ghosh AK, Tang J (2011) β-Secretase inhibitor GRL-8234 rescues age-related cognitive decline inAPPtransgenic mice. FASEB J 25, 775-784.
40. Tamashiro TT, Dalgard CL, Byrnes KR (2012) Primary microglia isolation from mixed glial cell cultures of neonatal rat brain tissue. J Vis Exp 66, 3791-3814.
41. Chiba K, Kawakami K, Tohyama K (1998) Simultaneous evaluation of cell viability by neutral red, MTT and crystal violet staining assays of the same cells. Toxicol In Vitro 12, 251-258.
42. Cardoso FL, Brites D, BritoMA(2010) Looking at the bloodbrain barrier: Molecular anatomy and possible investigation approaches. Brain Res Rev 64, 328-363.
43. Petit J, Meurice N, Kaiser C, Maggiora G (2012) Softening the Rule of Five-where to draw the line? Bioorg Med Chem 20, 5343-5351.
44. Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL (1999) Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett 463, 321-326.
45. Lenta BN, Vonthron-Sénécheau C, Weniger B, Devkota KP, Ngoupayo J, Kaiser M, Naz Q, Choudhary MI, Tsamo E, Sewald N (2007) Leishmanicidal and cholinesterase inhibiting activities of phenolic compounds from Allanblackia monticola and Symphonia globulifera. Molecules 12, 1548-1557.
46. Xie Q,Wang H, Xia Z, Lu M, ZhangW,Wang X, FuW, Tang Y, Sheng W, Li W, Zhou W, Zhu X, Qiu Z, Chen H (2008) Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem 51, 2027-2036.
47. Dawson WR, Windsor MW (1968) Fluorescence yields of aromatic compounds. J Phys Chem 72, 3251-3260.
48. Stine WB, Dahlgren KN, Krafft GA, LaDu MJ (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 278, 11612-11622.
49. Dinis TC, Maderia VM, Almeida LM (1994) Action of phenolic derivatives (acetaminophen, salicylate, and 5-aminosalicylate) as inhibitors of membrane lipid peroxidation and as peroxyl radical scavengers. Arch Biochem Biophys 315, 161-169.
50. Orlando RA, Gonzales AM,Royer RE, Deck LM,Vander Jagt DL. A chemical analog of curcumin as an improved inhibitor of amyloid Abeta oligomerization. PLoS One 7, e31869.